Danish biotech Actithera A/S has closed a $75.5 million Series A financing round to fund early clinical development of its lead radiopharmaceutical candidate targeting fibroblast activation protein (FAP). This candidate aims to leverage small-molecule pharmacokinetics to improve tumor targeting and therapeutic index. The financing supports Actithera's plans to establish the company’s clinical presence in the emerging radiopharmaceutical field, where novel agents are gaining traction for oncology treatments.